-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sibyman Biotechnology (CBMG) today announced the latest clinical application of a new CD19/CD20 dual-target CAR-T cell product C-CAR039 for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) Data
About this research
About this researchC-CAR039 is a new type of second-generation 4-1BB dual-target CAR-T with an optimized dual-specific antigen-binding domain, which can act on both CD19 and CD20 dual targets, and can eliminate CD19 in vivo and in vitro /CD20 single positive or double positive tumor cells
In the phase I clinical trials in China (NCT04317885, NCT04655677, NCT04696432, NCT04693676), a dose escalation and expansion study was conducted to evaluate the safety and effectiveness of C-CAR039 in patients with r/r B-NHL
Key findings and results
Key findings and resultsAs of April 20, 2021, 34 patients have received 1.
According to the ASTCT 2019 standard, cytokine release syndrome (CRS) and immune effector cell-related neurotoxicity syndrome (ICANS) are graded
As of the cut-off date, with a median follow-up of 7 months, the best overall response rate was 92.